MSD Signs a License Agreement with King’s College London & Wellcome’s Innovations to Develop Chronic Neuropathic Pain Therapies

 MSD Signs a License Agreement with King’s College London & Wellcome’s Innovations to Develop Chronic Neuropathic Pain Therapies

MSD Signs a License Agreement with King’s College London & Wellcome’s Innovations to Develop Chronic Neuropathic Pain Therapies

Shots:

  • King’s and Wellcome to receive $340M as development and commercial milestone and royalties on sales. MSD to get a license for conducting lead optimization, preclinical & clinical research
  • The focus of an agreement is to develop therapies for chronic pain and to meet unmet medical needs of patients
  • Professor McNaughton at King’s identifies target protein, HCN2 which is used by MSD to develop therapies that relieve pain without side effects by blocking HCN2 protein

Click here to read full press release/ article | Ref: King’s College London| Image: MSD

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post